Swiss drugmaker Novartis (SIX:NOVN) is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surrounding diversity in the U.S.

A number of U.S. and European companies have ditched or scaled back their diversity, equity and inclusion programmes since U.S. President Donald Trump declared some elements of DEI illegal and threatened to investigate companies over them.

Novartis said in a statement to Reuters that evolving laws and policies in the U.S. will require it to change, though the company continues to believe in “embracing varied perspectives and fostering equal opportunity for all of our people”.